Announcements Trials
Browse Landscape

Status

No longer available 1Approved for marketing 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 7Expanded_access 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Blast Crisis 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Accelerated Phase 1

Interventions

nilotinib 2fludarabine phosphate 1Whole-Body Irradiation 1Tacrolimus 1Mycophenolic Acid 1Cytarabine 1Cord Blood Stem Cell Transplantation 1Busulfan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Expanded_access × Blast Crisis × nilotinib × Clear all
NCT00905593 2012-07-18

ENACT

Novartis

Approved for marketing
MyeloidOther hematologic neoplasm

Blast Crisis, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00413270 2011-07-13

Oral Nilotinib in Adults With Chronic Myeloid Leukemia (CML) in Blast Crisis Who Are Imatinib Resistant or Intolerant

Novartis

No longer available
MyeloidOther hematologic neoplasm

Blast Crisis, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase

Data powered by HemOnc (CC BY 4.0) Colophon âš¡